Last $1.94 USD
Change Today -0.105 / -5.15%
Volume 5.5M
EXEL On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 3:44 PM 01/29/15 All times are local (Market data is delayed by at least 15 minutes).

exelixis inc (EXEL) Snapshot

Open
$2.05
Previous Close
$2.04
Day High
$2.11
Day Low
$1.87
52 Week High
03/5/14 - $7.58
52 Week Low
12/23/14 - $1.26
Market Cap
378.7M
Average Volume 10 Days
2.7M
EPS TTM
$-1.44
Shares Outstanding
195.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EXELIXIS INC (EXEL)

exelixis inc (EXEL) Related Businessweek News

No Related Businessweek News Found

exelixis inc (EXEL) Details

Exelixis, Inc., a biopharmaceutical company, develops small molecule therapies for the treatment of cancer in the United States. The company focuses primarily on developing and commercializing COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of patients with progressive, metastatic medullary thyroid cancer. It is also evaluating cabozantinib in various development programs comprising approximately 45 clinical trials, including 3 ongoing Phase 3 pivotal trials across multiple indications, with particular focus on Phase 3 pivotal trials in metastatic renal cell carcinoma (RCC) and advanced hepatocellular carcinoma (HCC). In addition, the company develops cobimetinib, an inhibitor of MEK, which is in Phase 3 pivotal trial evaluating in combination with vemurafenib in previously untreated patients with unresectable locally advanced or metastatic melanoma harboring a BRAFV600 mutation. Exelixis, Inc. has collaborations with Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.

227 Employees
Last Reported Date: 02/20/14
Founded in 1994

exelixis inc (EXEL) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $1.1M
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $681.7K
Compensation as of Fiscal Year 2013.

exelixis inc (EXEL) Key Developments

Exelixis, Inc. and Swedish Orphan Biovitrum AB Extend and Restructure Distribution Agreement for COMETRIQ® for Medullary Thyroid Cancer

Exelixis, Inc. announced that it has extended and restructured its agreement with Swedish Orphan Biovitrum AB to support the distribution and commercialization of COMETRIQ® (cabozantinib) for progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC) in the European Union (EU), Switzerland, Norway, Russia, and Turkey. The agreement, which was established in February 2013 and due to expire on December 31, 2015, will now extend to December 31, 2019. Moreover, the payment structure of the partnership will transition from fixed fees paid by Exelixis to Sobi to support initial build out of COMETRIQ European commercial infrastructure to a sales margin-based approach. Exelixis continues to maintain commercial rights for all other potential cabozantinib oncology indications on a global basis. Sobi exclusively markets, sells, and distributes COMETRIQ for its MTC indication in the covered territory of the European Union, Switzerland, Norway, Russia, and Turkey. In parts of the territory where COMETRIQ is not approved, Sobi administers a Named Patient Use program. Exelixis is responsible for regulatory approvals in the covered territory, and the company retains the ability to terminate the agreement at will at any time upon payment of certain pre-determined fees.

Exelixis Releases Results from the Final Analysis of COMET-2

Exelixis released results from the final analysis of COMET-2, a trial of cabozantinib in men with metastatic castration-resistant prostate cancer, showing the trial failed to meet its primary endpoint of alleviation of bone pain. The patients suffer from moderate to severe pain despite optimized narcotic medication, and whose disease has progressed following treatment with docetaxel as well as abiraterone and/or enzalutamide. In the trial, 15% of patients reported a pain response, compared with 17% of patients in the control group receiving mitoxantrone/prednisone. The difference in pain response wasn't statistically significant and the safety profile of cabozantinib in the trial was consistent with that observed in previous studies in mCRPC.

Exelixis, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 01:30 PM

Exelixis, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 01:30 PM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Michael M. Morrissey, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EXEL:US $1.94 USD -0.105

EXEL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CrystalGenomics Inc 12,600 KRW +200.00
CTI BioPharma Corp $2.19 USD -0.025
Curis Inc $1.88 USD +0.12
Cytokinetics Inc $7.45 USD +0.14
Rigel Pharmaceuticals Inc $2.12 USD +0.05
View Industry Companies
 

Industry Analysis

EXEL

Industry Average

Valuation EXEL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 18.0x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EXELIXIS INC, please visit www.exelixis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.